Risk of Diabetic Ketoacidosis Associated with Sodium Glucose Cotransporter-2 Inhibitors: A Network Meta-Analysis and Meta-Regression
<b>Background:</b> Sodium glucose cotransporter-2 inhibitors (SGLT2is) represent an emerging class of drugs with diverse indications. Despite their therapeutic potential, concerns regarding safety, particularly diabetic ketoacidosis (DKA), remain contentious, with uncertainty regarding d...
Main Authors: | Kannan Sridharan, Gowri Sivaramakrishnan |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/13/6/1748 |
Similar Items
-
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
by: Simes BC, et al.
Published: (2019-10-01) -
Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review
by: Julia Hoehlschen, et al.
Published: (2023-04-01) -
Differential In Vitro Effects of SGLT2 Inhibitors on Mitochondrial Oxidative Phosphorylation, Glucose Uptake and Cell Metabolism
by: Elmar Zügner, et al.
Published: (2022-07-01) -
Association between SGLT2 (sodium-glucose cotransporter-2) inhibitors and bladder cancer in individuals with type 2 diabetes; a systematic review and meta-analysis
by: Mobin Mohammadtabar, et al.
Published: (2023-03-01) -
Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions
by: Sanjay Kalra, et al.
Published: (2015-01-01)